Sugi Predict

Sugi Predict / Compounds / SCHEMBL29486242

SCHEMBL29486242

SCHEMBL29486242

CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)[C@@H](C)CC)[C@@H](C)O

nearest known ligand 0.62

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ KISS1R Q969F8 5/20 0.62
▸ VIPR1 P32241 4/20 0.61
▸ VIPR2 P41587 6/20 0.60
▸ TFPI P10646 1/20 0.58
▸ ECE1 P42892 1/20 0.56
▸ GLP1R P43220 1/20 0.56
▸ MUS81 Q96NY9 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31182826 0.91 VIPR1 (0.59) KISS1RVIPR1VIPR2TFPIECE1
SCHEMBL29875761 0.91 KISS1R (0.70) KISS1RVIPR1TFPI
SCHEMBL30578032 0.90 KISS1R (0.62) KISS1RVIPR1VIPR2TFPIECE1
SCHEMBL9401494 0.89 NPY4R (0.62) KISS1R
SCHEMBL29694508 0.89 VIPR2 (0.66) VIPR1VIPR2TFPIECE1GLP1R
SCHEMBL30495814 0.89 VIPR1 (0.71) VIPR1VIPR2TFPIECE1GLP1R
SCHEMBL30432941 0.88 VIPR1 (0.63) KISS1RVIPR1VIPR2TFPIECE1
SCHEMBL29972930 0.88 KISS1R (0.62) KISS1RVIPR1VIPR2
SCHEMBL29875567 0.88 KISS1R (0.68) KISS1RTFPI
SCHEMBL30974522 0.88 VIPR1 (0.61) KISS1RVIPR1VIPR2TFPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114745675-A Wi-Fi indoor positioning method based on improved GAN combined hypothesis test 重庆邮电大学 2022-07-12 — — CN claimed
US-12365736-B2 ALK7 binding proteins and uses thereof ACCELERON PHARMA INC. (US) 2025-07-22 — — US disclosed
US-20250051411-A1 COMPOSITIONS AND METHODS FOR USING ACTIN-BASED PEPTIDES TO MODULATE CELLULAR BIOACTIVITY AND CELLULAR SUSCEPTIBILITY TO INTRACELLULAR PATHOGENS VIRONGY L L C (US) 2025-02-13 — — US disclosed
US-20240287196-A1 ALK7 Binding Proteins and Uses Thereof ACCELERON PHARMA INC (US) 2024-08-29 — — US disclosed
EP-4374157-A2 FRET-BASED ASSAYS The General Hospital Corporation (US) 2024-05-29 — — EP disclosed
US-20240108687-A1 COMPOSITIONS AND METHODS FOR USING COMBINATIONS OF ACTIN-BASED PEPTIDES TO MODULATE CELLULAR BIOACTIVITY Virongy L.L.C. (US) 2024-04-04 — — US disclosed
US-20240035101-A1 METHOD FOR SELECTING ANTIGENIC VIRAL SEQUENCES FOR VACCINES AND THERAPEUTICS THE CURATORS OF THE UNIVERSITY OF MISSOURI 2024-02-01 — — US disclosed
CN-110036026-B Engineered two-part cell device for discovery and characterization of T cell receptor interactions with related antigens 杰诺维有限公司 2024-01-05 — — CN disclosed
US-20230416379-A1 ALK7 Binding Proteins and Uses Thereof ACCELERON PHARMA INC (US) 2023-12-28 — — US disclosed
EP-4291572-A1 COMPOSITIONS AND METHODS FOR USING COMBINATIONS OF ACTIN-BASED PEPTIDES TO MODULATE CELLULAR BIOACTIVITY Virongy L.L.C. (US) 2023-12-20 — — EP disclosed
CN-109219446-B ALK7 binding proteins and uses thereof 艾科赛扬制药股份有限公司 2023-03-28 — — CN disclosed
EP-4127169-A1 TARGETED DESTRUCTION OF VIRAL RNA BY CRISPR-CAS13 University of Rochester (US) 2023-02-08 — — EP disclosed
EP-4127170-A1 CRISPR-CAS13 CRRNA ARRAYS University of Rochester (US) 2023-02-08 — — EP disclosed
WO-2023004438-A2 FRET-BASED ASSAYS THE GENERAL HOSPITAL CORPORATION (US) 2023-01-26 — — WO disclosed
US-20220348685-A1 ALK7 BINDING PROTEINS AND USES THEREOF ACCELERON PHARMA INC. 2022-11-03 — — US disclosed
EP-4045662-A1 MATERIALS AND METHODS FOR THE TREATMENT OF DISORDERS ASSOCIATED MUTATIONS IN THE IRF2BPL GENE Research Institute at Nationwide Children's Hospital (US) 2022-08-24 — — EP disclosed
WO-2022174142-A1 COMPOSITIONS AND METHODS FOR USING COMBINATIONS OF ACTIN-BASED PEPTIDES TO MODULATE CELLULAR BIOACTIVITY AND CELLULAR SUSCEPTIBILITY TO INTRACELLULAR PATHOGENS Virongy L.L.C. (US) 2022-08-18 — — WO disclosed
CN-114745675-A Wi-Fi indoor positioning method based on improved GAN combined hypothesis test 重庆邮电大学 2022-07-12 — — CN disclosed
EP-3976656-A1 ALK7 BINDING PROTEINS AND USES THEREOF Acceleron Pharma Inc. (US) 2022-04-06 — — EP disclosed
CN-114245805-A ALK7 binding proteins and uses thereof 艾科赛扬制药股份有限公司 2022-03-25 — — CN disclosed
Send feedback